Beijing chest hospital participates in the project won the national science and technology progress award, first prize

2015 national science and technology awards on January 8, 2016 at Beijing's great Hall of the General Assembly was held, XI and other party and State leaders attending the General Assembly and for the winners. "The small Ecker for the hydrochloride molecular targeted cancer drug development, industrialization and application" project is the field of medicine was awarded the national science and technology progress award, first prize only one of the three projects, capital Medical University, Beijing chest hospital and Oncology Director Professor Zhang Shucai completed as part of the project completed and the people, to receive this honor.

IKE hydrochloride for dasatinib is China's first small molecule targeting of anticancer drugs, drugs have complete independent intellectual property rights, are "Eleven-Five" and "Twelve-Five" the outstanding achievements of major science and technology projects, has been awarded with many invention patents. In the drug discovery process, Director of Beijing chest hospital and Oncology Professor Zhang Shucai participate ICOGEN, CONVINCE and ISAFE and many national multicenter clinical study.

In August 2011, IKE for dasatinib by the Chinese State food and Drug Administration (CFDA) approved, for advanced non-small cell lung cancer (non-small cell lung cancer,NSCLC) treatment, breaking the monopoly of imported drugs in this area. November 2014 Ecker for the approval of the CFDA for the first-line treatment of EGFR (epidermal growth factor receptor, epidermal growth factor receptor) gene mutation sensitive indication of advanced NSCLC, after gefitinib, which is the second in China to receive the indication EGFR-TKI (epidermal growth factor receptor tyrosine kinase Inhibitor, epidermal growth factor receptor tyrosine kinase inhibitor) targeted drugs. In 2015, the Beijing chest Hospital Oncology Director Professor Zhang Shucai led by IKE for the sensitive mutations of Exon Dominican treatment of EGFR21 advanced non-small cell lung cancer randomized, open, prospective, multicenter clinical study (NCT02404675), and explore new ways of targeted therapy for non-small cell lung cancer, and development of new targeted therapy for advanced non-small cell lung cancer. Also, Beijing chest section Hospital Oncology currently also bear with more items Ecker for the Nepal in Institute clinical research project, involved brain transfer patients, and old mutation patients, and and radiotherapy joint application, and early patients operation Qian new auxiliary and operation Hou auxiliary research,, part early research results has in world lung cancer Assembly (WCLC), and United States clinical tumor learned annual (ASCO) and the Lancet Oncology, global authority tumor magazine Shang announced and published.

"Small molecule targeted anti-cancer drug IKE for dasatinib" was awarded the national science and technology advancement Awards, first prize, this is the first time China's pharmaceutical industry to receive this honor. IKE hydrochloride for dasatinib is China's first small molecule targeting of anticancer drugs, the first indications are for advanced non-small cell lung cancer, breaking the monopoly of imported drugs in this area. Completed the project unit, the Beijing chest hospital affiliated to capital Medical University, as the only medical systems unit to receive this honor.

National Science and technology progress award, was established by the State Council, one of the State Science and technology awards 5 Awards (State Supreme science and technology award, the State Natural Science Award, the State technological invention award, the State Science and technology progress award, international science and technology cooperation Award). This award is intended to encourage research, technological development, technological innovation, promote the use of advanced scientific and technological achievements, to promote high-tech industrialization, and completion of major scientific and technological projects, plans made creative contributions to Chinese citizens and organizations in the process. National Awards for science and technology progress Awards covering all sectors of the national economy, is an extensive science and technology awards. The award is organized by the Ministry of science and technology review, the State Council issued a national top science and technology award, not only by leaders of the Party Central Committee and the State Council attach great importance to also become the focus of industry and even the whole society. 2015 national science and technology progress award, first prize a total of 17 items, medicine projects in the area of 3, "small Ecker for the hydrochloride molecular targeted cancer drug development research, industrialization and application" project is one of them.

Capital Medical University, Beijing chest hospital, the Beijing thoracic Tumor Research Institute of tuberculosis with chest tumor and tuberculosis patients as the main service object, medical treatment, scientific research, education, prevention as one of the three levels of first-class hospital. And set and set "WHO TB research training cooperation Center", and "national drug clinical test institutions", and "China CDC TB control Clinical Center", and "Beijing lung cancer clinic Center", and "Beijing bone joint TB clinic Center", is national first Dr and master degree grant units, has MRI, and spiral CT, and meet line SPECT, and DR imaging system, and line Accelerator, and Molecular Pathology diagnosis, chest tumor diagnosis, and treatment of full equipment. Hospital breast cancer multidisciplinary collaboration Center has sent many people to United States m. D。 Anderson Cancer Center and other well-known foreign cancer centers studying learning and Exchange, formed a "domestic first-class, internationally renowned" cancer multidisciplinary team.

By hospital always insisted clinical and research combined, constantly develop innovation, relies on Yu Beijing tumor molecular biology laboratory lung cancer points room, and molecular biology laboratory, and drug learn research, and animal laboratory, based research department, carried out various lung cancer related based and clinical research, completed domestic first human lung transplant, and first established has domestic human lung cancer cell Department, and more early carried out chest tumor violations Shang cavity vein system vascular of surgical treatment, more than 20 more than items results fill has domestic blank. As a base for drug clinical trials, has carried out a number of new domestic and international multi-center clinical study of tumor. Many State "863 Program", "the 973Plan ", National Science Foundation, the national" XV research "and" Eleven-Five "," Twelve-Five "major science and technology projects, such as research projects. The Beijing chest hospital affiliated to capital Medical University, actively advocates the establishment of a learning organization, promoting the construction of hospital culture, adhere to the people-oriented, accelerating the discipline construction and talent training, continue to promote soft power and core competitiveness, building on behalf of the breast cancer professional high-quality personnel, for every one who provides international standards of diagnosis and treatment in cancer patients, enjoy international medical services.